Serum β 2 -microglobulin predicts mortality and transplant outcomes

Serum beta-2 microglobulin concentration predicts cardiovascular and all-cause mortality.

SERUM IgE AND BETA 2 MICROGLOBULIN LEVELS AFTER MYOCARDIAL INFARCTION

Serum IgE and beta 2 microglobulin levels were determined in 31 patients suffering from acute myocardial infarction and 30 patients with other forms of ischemic heart disease. The levels of these parameters were studied on the first, third and seventh day after the onset of disease. The immunological method used for the determinations was ELISA Patients with myocardial infarction showed an...

Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.

BACKGROUND AND OBJECTIVES Secondary analysis of the Hemodialysis Study showed that serum beta(2)-microglobulin levels predicted all-cause mortality and that high-flux dialysis was associated with decreased cardiac deaths in hemodialysis patients. This study examined the association of serum beta(2)-microglobulin levels and dialyzer beta(2)-microglobulin kinetics with the two most common causes ...

Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study.

In the randomized Hemodialysis (HEMO) Study, chronic high-flux dialysis, as defined by higher beta-2 microglobulin (beta(2)M) clearance, compared with low-flux dialysis did not significantly alter all-cause mortality in the entire cohort but was associated with lower mortality in long-term dialysis patients. This analysis examined the determinants of serum beta(2)M levels and the associations o...

The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis.

We examined the relationship between serum and bronchoalveolar lavage (BAL) galactomannan index (GMI) values and mortality in allogeneic hematopoietic cell transplant recipients with invasive pulmonary aspergillosis. Using a clinical sign and symptom-initiated approach, we found that the serum but not the BAL GMI level correlated with 42- and 180-day patient mortality.